Q&A: GSK Regulatory Head Huckle Talks About Life Under FDASIA
Executive Summary
GlaxoSmithKline Chief Regulatory Officer Paul Huckle discusses the big pharma’s experience with the PDUFA V review “program” for new molecular entities, the “breakthrough therapy” pathway and FDA’s patient-focused drug development initiative.